Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 87 clinical trials
Dasatinib In Waldenström Macroglobulinemia

This is Phase I pilot, single center study designed to explore the safety of Dasatinib in symptomatic Waldenström Macroglobulinemia participants who are progressing on ibrutinib therapy with BTK

igm level
platelet count
lymphadenopathy
immunoglobulin
ibrutinib
  • 2 views
  • 05 Apr, 2022
Personalized Multi-peptide Vaccination in CLL Patients

ibrutinib-based regimes.

lymphocytosis
night sweats
fatigue
flow cytometry
lymphadenopathy
  • 0 views
  • 18 Sep, 2021
  • 1 location
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

during treatment with ibrutinib or acalabrutinib.

ibrutinib
17p deletion
measurable disease
chronic lymphocytic leukemia
acalabrutinib
  • 4 views
  • 21 Mar, 2022
  • 5 locations
Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients

In this biological study, blood samples will be collected from patients with CLL treated with targeted agents (ibrutinib and venetoclax) to assess the impact of these treatments on the

ibrutinib
venetoclax
  • 0 views
  • 21 Mar, 2022
  • 2 locations
Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma (ALTAMIRA)

bruton tyrosine kinase (BTK) inhibitor, more selective than ibrutinib, and without in vitro antagonism of anti-CD20 directed immunotherapies, indicating that its combination with rituximab may be more

btk inhibitor
platelet count
TP53
mantle cell lymphoma
acalabrutinib
  • 0 views
  • 21 Mar, 2022
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

, mantle cell lymphoma, or marginal zone lymphoma patients who have become intolerant of prior ibrutinib and/or acalabrutinib treatment, by comparing intolerance to adverse event profile as assessed by the

leukemia
lymphoma
b-cell lymphoma
platelet count
lymphoid leukemia
  • 108 views
  • 28 Jun, 2022
  • 29 locations
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

with obinutuzumab (V+G, Cohort 1) or with ibrutinib (V+I, Cohort 2) in Japanese participants with previously untreated CLL/Small Lymphocytic Lymphoma (SLL). Adverse events and change in disease

ibrutinib
obinutuzumab
lymphoma
chronic lymphocytic leukemia
venetoclax
  • 0 views
  • 03 May, 2022
  • 19 locations
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

monotherapy treatment at the recommended dose. A separate Phase 1 cohort will assess the combination of JCAR017 and concurrent ibrutinib. Another separate Phase 1 cohort will assess the combination of JCAR017

gilbert's syndrome
flow cytometry
lymphoma
lymphoid leukemia
lymphadenopathy
  • 59 views
  • 09 Jul, 2022
  • 32 locations
A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)

combination with ibrutinib Arm E: JCAR017 in combination with relatlimab and/or nivolumab Arm F: JCAR017 in combination with CC-99282 Additional arms will be added by way of amendment once combination agents

nivolumab
b-cell lymphoma
large b-cell lymphoma
indolent non-hodgkin lymphoma
ibrutinib
  • 60 views
  • 09 Aug, 2022
  • 10 locations
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

combination with oral ibrutinib and oral lenalidomide in participants with with R/R DLBCL. Arm 3: SC epcoritamab in combination with intravenous (IV) polatuzumab vedotin, IV rituximab, IV

b-cell lymphoma
large b-cell lymphoma
prednisone
rituximab
doxorubicin
  • 0 views
  • 09 Aug, 2022
  • 6 locations